This HTML5 document contains 175 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q38617638
rdf:type
wikibase:Item
schema:description
mokslinis straipsnis 2017年學術文章 2017年學術文章 artículo científico publicado en 2017 мақолаи илмӣ научни чланак научни чланак vedecký článok article científic مقالهٔ علمی ২০১৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ научна статия bài báo khoa học мақолаи илмӣ artikull shkencor tieteellinen artikkeli επιστημονικό άρθρο videnskabelig artikel (udgivet 2017) مقالة علمية wissenschaftlicher Artikel מאמר מדעי 2017 nî lūn-bûn 2017年學術文章 vetenskaplig artikel บทความทางวิทยาศาสตร์ article scientifique (publié 2017) artigo científico articol științific vědecký článek 2017年学术文章 2017年學術文章 scienca artikolo artigo científico (publicado na 2017) 2017年學術文章 naučni članak 2017년 논문 teaduslik artikkel articolo scientifico 2017年学术文章 artículu científicu espublizáu en 2017 2017年学术文章 ശാസ്ത്രപ്രബന്ധം​ научная статья tudományos cikk scientific article vitskapeleg artikkel artykuł naukowy artikulong pang-agham wetenschappelijk artikel 2017年学术文章 2017年の論文 наукова стаття, опублікована в серпні 2017 سائنسی مضمون գիտական հոդված 2017年學術文章 article scientific bilimsel makale vitenskapelig artikkel artigo científico (publicado na 2017) სამეცნიერო სტატია 2017年学术文章
p:P577
wds:Q38617638-6A0A6DDB-FF93-49E1-986A-D590401F10D6
wdt:P577
2017-08-16T00:00:00Z
p:P407
wds:Q38617638-DC89849E-D503-467D-B00B-7D54870865E2
wdt:P407
wd:Q1860
p:P2860
wds:Q38617638-EB1AEF09-1399-4782-B17A-990ACEF8DBD9 wds:Q38617638-EFAD0277-AA2D-4CE3-8610-5BB8E03C8C32 wds:Q38617638-CB2F6A51-740D-4527-80AB-7E5D7681F160 wds:Q38617638-D99E094A-86FD-4FDE-968D-DA5227F8DDF9 wds:Q38617638-C155E118-4C83-4E25-AEDA-56DD549F446D wds:Q38617638-C774B955-07D1-4F91-8B66-370E9A6E6D41 wds:Q38617638-9CC8D65F-4DCD-42F4-B672-3A2618625F8A wds:Q38617638-A68C8359-463B-44AA-94B2-5078500C9215 wds:Q38617638-ADCCE42E-246A-40A0-B5C6-13C88C766510 wds:Q38617638-AE22909C-E0CC-4497-8CDB-CF61DF758390 wds:Q38617638-8AC42B5E-B6DB-4801-9C80-7F1F520C80B8 wds:Q38617638-8CDB0C36-6FF3-4D6D-821D-5D896B3FAFC5 wds:Q38617638-77ED30C2-0461-40F2-AEE6-3D43834DD4B6 wds:Q38617638-820899A0-F8F6-4DD7-90DF-F621BA82EF77 wds:Q38617638-76400254-B80E-413A-9770-9FDC1C1041E3 wds:Q38617638-51475B7F-E9E6-4EFC-B0C5-ACF87051A017 wds:Q38617638-5B233F89-07F3-4C7F-8BA7-43F0922F897B wds:Q38617638-38307DE1-FEC8-4318-BAD0-A2E91F28A491 wds:Q38617638-3B2EDBBC-1267-409D-B09D-F73E58000BC4 wds:Q38617638-303068CA-C5CE-46B1-9D51-2D02E3BC9140
wdt:P2860
wd:Q51326518 wd:Q29618134 wd:Q56622251 wd:Q53131740 wd:Q39396355 wd:Q29615443 wd:Q27861062 wd:Q45894179 wd:Q30890582 wd:Q38493811 wd:Q29620657 wd:Q38732543 wd:Q58024613 wd:Q34616628 wd:Q38586991 wd:Q36841621 wd:Q27860852 wd:Q54196202 wd:Q41501755 wd:Q24594790
p:P2093
wds:Q38617638-BA41CDA3-4147-44EC-94E1-DBE1D26342B3 wds:Q38617638-95E772CD-C7D9-4283-83B5-F08AE1F8CEE0 wds:Q38617638-CA3C374D-CD25-41F0-A3ED-E8F135637CFF wds:Q38617638-1E356026-BD71-4D1D-A597-5F8B91CD37BD wds:Q38617638-1292288E-6D0F-477E-ACBF-E799D7A90945 wds:Q38617638-089361AE-EAC3-4DF8-B278-66B982273DC6 wds:Q38617638-4E968582-7A2E-4043-AA23-25B08F6F23B7 wds:Q38617638-76E0F876-19CD-4E2F-95D6-778B7A288DE1 wds:Q38617638-74E8E753-E230-4329-9DF3-6A4BD2373E36 wds:Q38617638-40AFED84-ADC5-4FF1-A86C-416BC717A1AC
wdt:P2093
Scot Ebbinghaus Matteo S Carlino Bart Neyns Nageatte Ibrahim Jean-Jacques Grob Teresa M Petrella Omid Hamid Honghong Zhou James Larkin Catriona McNeil
rdfs:label
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
skos:prefLabel
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
schema:name
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
p:P50
wds:Q38617638-7D3DF394-9AFE-43E4-B25A-0632D935A4E0 wds:Q38617638-7FFC18EA-86AB-49F7-8B21-ACF55B428B83 wds:Q38617638-D7EBB741-D7DF-4A13-AA4E-ACE549DA27A5 wds:Q38617638-DDC2CFA5-3172-4B5D-BF6C-A4E58A095F84 wds:Q38617638-F40EB15E-00EA-4FC0-8189-3E1D3D60EF46 wds:Q38617638-1715AEB8-8646-4A6A-944E-3A9A62172E6A wds:Q38617638-235C77BA-8815-412D-816C-4287497A45E2 wds:Q38617638-3233D4B1-2F76-4F94-B47F-50A78DE37AFF wds:Q38617638-3E13C221-E77C-4296-9AF8-F77D030405F2 wds:Q38617638-3F570562-3740-48A2-9562-BEABE39FB3C7 wds:Q38617638-404528C0-61B7-41BF-8784-ED6BCCF629CF
wdt:P50
wd:Q32649737 wd:Q41784107 wd:Q55651283 wd:Q40580858 wd:Q42645931 wd:Q89370036 wd:Q42947998 wd:Q32649604 wd:Q58300362 wd:Q49880375 wd:Q92180485
p:P1476
wds:Q38617638-AEDEA424-3BA7-412E-8DB9-E486C222E759
wdt:P1476
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
p:P31
wds:Q38617638-94AA6306-057B-4FBD-8EA7-564EA8CE1506
wdt:P31
wd:Q13442814
p:P921
wds:Q38617638-3B23F1FB-80A9-4958-B5DA-C4DC1311CF1C wds:Q38617638-17738BEC-E046-48FA-8BA2-9C9C803CA6C6 wds:Q38617638-212AC594-55FE-4C8D-8CFC-D3AFB3260D0B
wdt:P921
wd:Q13896859 wd:Q2459042 wd:Q6934595
p:P698
wds:Q38617638-32F1DEBE-B1CA-4D95-A96D-2419667D6FE0
wdtn:P698
n12:28822576
wdt:P698
28822576
p:P1433
wds:Q38617638-6CE8CFB7-EA0F-4AD2-8BE5-4A9B4F364E86
wdt:P1433
wd:Q939416
p:P356
wds:Q38617638-049CEA37-9A4A-4E86-BD81-6BFB17749830
wdtn:P356
n11:S0140-6736(17)31601-X
wdt:P356
10.1016/S0140-6736(17)31601-X